Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Exclusion Criteria

• •Laboratory values of:
• •* Absolute neutrophil count \< 1500/ul;
• •* Platelet count \< 75,000/ul;
• •* Hemoglobin \< 10 gm/dl;
• •* AST or ALT \> 3 x the upper limit of normal (ULN);
• •* Alkaline phosphatase \> 5 x ULN;
• •* Bilirubin \> 2 x ULN;
• •* Serum creatinine \> 2.0 mg/dL.
• •Symptomatic or uncontrolled (untreated or treated and progressing) brain metastasis.
• •Evidence of meningeal metastasis.
• •Greater than one prior cytotoxic regimen (not counting adjuvant or neoadjuvant cytotoxic chemotherapy if completed \> 12 months prior to cytotoxic regimen).
• •Chemotherapy, radiation therapy, experimental therapy, immunotherapy or systemic biologic anticancer therapy within 21 days before beginning study treatment.
• •Significant weight loss \> 10% of body weight in preceding 6 weeks.
• •Treatment for another cancer within 3 years of enrollment, unless basal cell carcinoma or cervical cancer in situ.
• •Myocardial infarction within 6 months of enrollment or congestive heart failure rated New York Heart Association (NYHA) Class III or IV.
• •Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg and diastolic blood pressure \> 110 mm Hg on maximal medical therapy).
• •Known history of porphyria (testing not required at screening visit).
• •Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening visit).
• •Known history of HIV infection (testing not required at screening visit).
• •Female who is pregnant or lactating (serum pregnancy test is required for all female patients of childbearing potential).
• •Sexually active male or female of childbearing potential unwilling to use adequate contraceptive protection.
• •Physical or mental condition that makes patient unable to complete specified follow-up assessments.